- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Tms Co. Ltd.
Industry Sector: CommercialServices
CEO: N/A
Number Of Employees: N/A
Enterprise Value: N/A
PE Ratio: -8.3
Exchange/Ticker 1: Tokyo:4891
Exchange/Ticker 2: N/A
Latest Market Cap: $40,305,712
BioCentury | Apr 25, 2023
Product Development
Viehbacher takes first steps in Biogen redesign
Stops development of high-risk stroke programs, exits ophthalmology research
BioCentury | May 13, 2021
Product Development
May 12 Quick Takes: Biogen-TMS in stroke deal; plus Minerva, Autobahn-Astellas, Emergent, Magenta, Fosun-BioNTech
Biogen Inc. (NASDAQ:BIIB) is exercising an option to acquire a next-generation thrombolytic agent from TMS Co. Ltd. The move comes after the Japanese company showed TMS-007 reopened blood vessels and
BioCentury | Aug 7, 2020
Deals
Billion-dollar Biogen deal gives Denali fuel to validate CNS delivery platform
Denali to advance lead Parkinson’s program, BBB-penetrant candidates with cash infusion from Biogen
BioCentury | Mar 4, 2019
Distillery Therapeutics
Inhibiting soluble epoxide hydrolase for renal damage
Items per page:
1 - 6 of 6